introduction Cancer develops and progresses by genetic aberrations expressed as many changes in chromosomes and DNA. Thereby, on the one hand microscopically detectable increases or decreases in the numbers of entire chromosomes as well as gains and losses of chromosomal stretches occur. On the other hand at the molecular level of DNA deletions, amplifications and base exchanges are also observed that have an impact on gene function and expression. It is still under debate which process of the two is the dominant cancer cause and promoter of cancer progression. Nevertheless, clonal selection during cancer development leads to the establishment of a dominant cancer cell subpopulation which harbours distinct genetic aberrations which can be used to classify cancer for prognosis and therapy prediction. The non-ambiguous relationship between the genotype of distinct loci and the phenotype is physiologically a rare event and therefore, highly selective in cancer. Although contemporary genetics have shown that quantitative trait loci exist [1] , it is unlikely that the gene dosage sensitivity for a single locus significantly changes the phenotype of normal somatic cells. However, specific gene families, e.g. those involved in essential signal transduction systems, show such dosage sensitivity in cancer [2] . The most prominent example of those genes is the HER receptor family, most prominently HER2, which induces signal transduction for survival, proliferation and migration [3] . The interaction of the gene products is often the reason for such gene dosage sensitivity. Subsequent direct interactions or downstream pathway crossings with other proteins might lead to a modification of the effect of gene dosages and result in a subtle variety of phenotypes ( Figure 1 ). To find the decisive phenotype requires enlightening the structure of the genomic 'chaos' in cancer by the determination of striking genomic events on the background of genetic noise.
high-resolution methods for oncogenomics enable the detection of distinct multi-gene genomic aberration blocks [4] . The method was used mainly to determine the amount and length of polymorphic CA simple sequence repeats on capillary electrophoresis and allowed the detection of so-called 'loss of heterozygosity' (LOH) down to a resolution of several thousand base pairs at distinct loci [5] .
The detection of all unbalanced cytogenetic aberrations within a tumor cell became possible by the simple approach of comparative genomic hybridization (CGH) [6] . The lack of resolution of CGH (5-8 Mb) could be overcome by the sequential application of CGH and microsatellite analysis [7] .
Using these approaches numerous studies demonstrated the presence of specific chromosomal aberrations in many different tumor types which have been considered so far as genomic noise caused by oncogene activation and/or suppressor gene loss of function [8] . The majority of the non-random chromosomal aberrations in cancer turned out to be gains of larger regions rather than losses or proved to be narrow high-level amplifications, as for the above-mentioned HER2 gene [9] .
Recently, the introduction of array technologies for CGH and expression analysis allowed the analysis of cancer genomes and transcriptomes by the genome-wide measurement of each single gene. Thereby, arrays were applied containing large bacterial artificial chromosome (BAC) probes or short probes targeting single nucleotide polymorphisms (SNPs) [10] [11] [12] .
The BAC array type has high genome sequence coverage but cannot detect precisely every gene. In contrast SNP arrays probe every gene, in some instances several times but have a low overall coverage of the genome sequence. In consequence due to these limits decisive genes which are located in a block of genomic aberration might be overlooked. In a subsequent paragraph we will demonstrate such a case for prostate cancer. Nevertheless, arraybased analysis demonstrated correlations between DNA copy number alterations and expression of the genes mutated by genomic aberrations and substantiated that chromosomal aberrations contain blocks of genes which provide an efficient way for cells to acquire a malignant, conceivable metastatic and drugresistant, phenotype (Table 1) [13, 14] . Specific gene-targeting analysis methods as such fluorescence in situ hybridization (FISH) and quantitative PCR (qPCR) confirmed array data and enabled the detection of specific genomic aberrations for cancer diagnostics, e.g. HER2 measurement in breast cancer [15] . Phenotypes represent the superposition of all cellular biochemical pathway activities that are partly regulated by the transcriptional levels of the functional proteins. As such, in addition to technical reproducibility and selective bioinformatic data, the analysis of biological master conditions needs to be defined in order to pick up on clinically relevant gene clusters from oncogenomic analyses [16] . The main classes of master conditions that serve to define a phenotype are the absolute levels of expression of gatekeeper or bottle neck proteins ('deepest hit'). With respect to cancer this is usually the case if chromosomal instability (CIN) leads to a dominant loss of genes on a distinct chromosomal stretch. For breast cancer this has been described for the loss of chromosome 16q. The 16q loss indicates a large subgroup of prognostic favorable estrogen receptor-positive breast cancers [17] . Conversely the relative levels of expression of interacting genes determine a phenotype ('dominant switch'). The most prominent example of this class is the specific activation of the tyrosine kinase receptor HER2 by amplification and its interaction with the sister receptor epidermal growth factor receptor (EGFR) and HER3. Clinical studies by immunohistochemistry on breast cancer tissue using antibodies against HER2 and EGFR have demonstrated that the subgroup that was positive for both HER2 and EGFR had the poorest prognosis [18] .
synergisms of genes located in one genomic aberration block: LOXL2 and Nkx3.1 foster prostate cancer progression
Besides genetic hot spots detected on chromosomes 10q and 17q the loss of 8p is frequently observed in prostate cancer [19] . From microsatellite analysis on chromosome band 8p21-22 in prostate cancer a common deletion interval was found [20] . Microsatellite analyses narrowed the interval to a 50 kb DNA stretch between the two markers D8S258 and NEFL. Deletion of homeobox gene NKX3.1 was already revealed as a key event in prostate cancer progression leading to increased proliferation and reduced apoptosis (Figure 1 ). Fine mapping of the region by real-time-PCR-based quantitative SNP analysis revealed the LOXL2 gene located 200 kb away from NKX3.1 as the most frequently deleted gene ( Figure 2 ) [21] . Simultaneous deletion of NKX3.1 and LOXL2 was observed in many prostate cancer cases. On protein level LOXL2 showed high expression in benign prostate tissue and rather low expression in most prostate cancer tissues. Intermediate expression was detected for prostatic intraepithelial neoplasia (PIN), which supports the assumption that LOXL2 is reciprocally associated with tumor progression to an invasive phenotype. For tumors displaying elevated LOXL2 expression a significant association with proliferation (Ki-67) and increasing Gleason pattern was found. This substantiates that a synergism of LOXL2 and NKX3.1 exists (see also Figure 1 ) and supposes LOXL2 to be an additional progression marker beside NKX3.1 for prostate cancer [22] . Annals of Oncology symposium article translating genetic pathways to protein networks by immunohistochemistry on tissue microarrays
As mentioned above DNA array methods have been introduced into research in genomic aberrations during the past years. Providing a new approach to the analysis of genomic aberrations, these new techniques generate a plethora of new data in a relatively short time. Along with these technical developments, new tools for the clinical evaluation of these large sets of data at a protein level need to be proved for diagnostics and therapy prediction. Tissue microarray (TMA) technology is one of these new tools [23] based on the simultaneous analysis of hundreds of intact tissues in parallel. The potential and the scientific value of TMAs in modern research have been demonstrated in an exponentially increasing number of studies [15] . For example the co-deletion on chromosome 8p21-22 of LOXL2 with NKX3.1 in prostate cancer was confirmed at the protein level by performing immunohistochemistry on TMAs from >1000 independent cases [21] . Furthermore, significant associations of weak LOXL2/NKX3.1 staining and proliferation (Ki-67) and apoptosis associated protein (XIAP) expression as well as differentiation (cytokeratin) and adhesion molecule (E-cadherin) expression could be shown simultaneously. The data give a complete picture of the impact of LOXL2 on the biology of the tumor and if available also on prognosis or therapy benefit.
The construction of a successful TMA starts simply with the careful selection of donor tissues and precise recording of their localization details. There are clear differences in the distribution of the work-up time required for the individual steps in the conventional slide by slide immunohistochemistry and the TMA approach. With the use of TMAs, most of the work time is now focused on the preparation of the TMA, in contrast to the conventional approach, where a large proportion of time and materials is spent on sectioning and labeling. The tissue array instrument is commercially available and is still very similar to the prototype system used during the early development of the TMA technique. Donor tissue is dissected by core needles with varying diameters. Tissue cores are punched from a predefined region of a donor paraffin waxembedded tissue block. Tissue cores are transferred to a recipient paraffin wax block, into a ready made hole, guided by a defined x-y position. This technique minimizes tissue damage and still allows sections to be cut from the donor paraffin wax block with all necessary diagnostic details, even after the removal of multiple cores. With the generation of 'frozen arrays', using fresh frozen tissue, even the last limitations of non-detectable proteins will also disappear. Nevertheless, the method still depends on the specificity of antibodies directed to epitopes of the target protein. Future developments might combine TMA with specific mass spectroscopy imaging methods which allow the detection of thousands of molecules in parallel. 
